PATENT CLAIM ANALYSIS

Application Number: 15757687
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2019-02
Patent Classification: ["424", "204100"]

Abstract:
The present invention relates to augmenting the effects of adoptive T cell therapy, such as TVAX Immunotherapy, using adjunct treatment with an oncolytic virus, such as a vaccinia virus, to treat various types of cancer or other proliferative disorders. Immunomodulatory compounds can be used to further augment to effects of the therapy.

Claim (Index 22):
The method of any of  claims 1 - 20 , wherein the oncolytic virus has been genetically engineered to encode a gene product selected from the group consisting of an anti-cancer agent, an anti-angiogenic agent, an immunomodulatory molecule or an antigen (e.g., cancer (neo)antigens, cancer-associated antigens, tissue-specific antigens, bacterial antigens, viral antigens, yeast antigens, fungal antigens, protozoan antigens, parasite antigens and mitogens), a hormone, a growth factor, a cytokine, a chemokine, a costimulatory molecule, a ribozyme, a transporter protein, a single chain antibody (e.g., an anti-VEGF or anti-VEGFR, or anti-EGFR antibody), an antibody (agonistic or antagonistic) against immune modulating proteins, an antisense or ds RNA or other RNA product, a prodrug converting enzyme, an siRNA, a microRNA, a toxin, an anti-cancer oligopeptide, a mitosis inhibitor protein, an antimitotic oligopeptide, an anti-cancer polypeptide antibiotic, an angiogenesis inhibitor, a cancer suppressor, a cytotoxic protein, a cytostatic protein, an enzyme that modifies a substrate to produce a detectable product or signal, an enzyme detectable by antibodies, a protein that can bind a contrasting agent.

Metadata:
- Claim Count in Document: 52.0
- Percentile: 90.0
- Lexical Diversity: 1.34884
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15892247', '14792424', '14004546', '15129916', '13470558']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7808831147759814
- 35 USC 102 Novelty (BERT): 0.5077130455630173
- Combined Prediction Score: 0.753566107854685
- Mean Citation Score: 263.860032
- Max Citation Score: 281.17853
- Similarity Product: 200.7317017114568

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test